COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Non-metastatic With Cancer

This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.

Research Base: Gary Morrow
NCT ID: NCT03186638
NCI Protocol Number: URCC-16092
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Condition

Cognitive Impairment, Malignant Neoplasm

Trial Type

Comparative Effectiveness Research

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP